TAONas-LUAD Project
TAONas-LUAD is coordinated by CRG (Barcelona) and with INSERM (Montpellier), SINTEF (Throndheim) and Inveniam Group (Barcelona) as part of the consortium. The main objective of the project is to develop an innovative therapy based on the use of Antisense Oligonucleotides (AONs) that regulate NUMB alternative splicing (AS). TAON will optimize AONs by improving their chemistry, formulation and administration and carry out regulatory preclinical studies to pave the way to the first application of AON-based splicing modulation in clinical oncology.
The Elephants
Involved
Our Role
- Public Funding
- European Consortium
- Research Development
- Communication & Dissemination Support
TAONas-LUAD and
Inveniam
Inveniam is a beneficiary in TAONas-LUAD and plays a mainly strategic, regulatory, and business-oriented role. It leads WP5 (IP and regulatory activities) and WP6 (business development and venture building), where it updates the exploitation plan, supports regulatory strategy and the EMA ITF interaction, prepares the go-to-market and business plans, develops fundraising materials, and supports investor outreach and spin-off creation. It also leads Task 7.4 on external communication and engagement within WP7.